Latest Convertible Notes News

Noxopharm signed a strategic MoU with Tezcat Biosciences, published major Sofra RNA research, and appointed Dr Olivier Laczka as CEO, while reporting positive safety data from its HERACLES trial and improving cash flow.

Tartana Minerals has raised $4.5 million to accelerate drilling and boost copper sulphate production, underpinning its extensive critical metals portfolio in Far North Queensland.

Papyrus Australia (ASX: PPY) has secured $175,000 through a share placement alongside convertible note conversions and related party loans, aiming to fund commercialisation and fulfil a key contract for biodegradable Collar Keeper® products.

Tolu Minerals has raised AUD 23.75 million through convertible notes from Petrosea, reinforcing its capital position ahead of shareholder approval. The company is also shoring up diesel supplies to safeguard operations at its Tolukuma Gold Mine amid global fuel volatility, while early drilling results hint at further resource potential.

Wellnex Life has pushed back the repayment deadline on nearly $3 million owed to former directors by three months, agreeing to additional fees and interest. Former CEO Zack Bozinovski returns as a consultant, suggesting ongoing strategic recalibration.

Core Lithium has greenlit the restart of its Finniss Lithium Project with a fully funded A$290 million package, initiating mining activities and targeting spodumene concentrate production by September 2026.

Airtasker Limited posted robust 3Q26 results highlighted by strong Australian marketplace momentum and explosive growth in the UK and US. The company reaffirmed its FY26 guidance, underpinned by strategic media partnerships and a solid cash position.

Syrah Resources has closed its retail entitlement offer, securing A$61 million and pushing total equity raised to A$104 million. AustralianSuper’s stake will approach half the company as Syrah prepares to fund key projects and advance strategic funding talks.

BCAL Diagnostics has expanded its Avantect cancer blood tests nationally through major pathology networks, generating $88,000 in Q3 revenue from 91 tests. The company also submitted an initial Medicare reimbursement application for pancreatic cancer detection and is preparing to launch an enhanced BREASTESTplus 2.0 test in early 2027.

Patagonia Lithium has reported strong assay and porosity results from its Formentera project in Argentina, alongside a successful $2.79 million capital raise that lifts its cash position to $3.4 million. The company is advancing drilling, seismic surveys, and plans for a 1,000 tonne lithium carbonate demonstration plant.

Terramin Australia has advanced its flagship Tala Hamza Zinc Project into early development with strong Algerian government backing and a revised 2.0Mtpa mining study. Meanwhile, a court ruling returned the Bird in Hand Gold deposit to the company, prompting strategic reviews, all while the group manages a tight cash position supported by a recent $1 million share placement.

Invion Limited is broadening its non-melanoma skin cancer trial to include basal cell carcinoma patients following encouraging safety and efficacy data from squamous cell carcinoma cohorts, targeting the largest skin cancer segment.